Otonomy to Report First Quarter 2022 Financial Results and Provide Corporate Update

Rhea-AI Summary

Otonomy, Inc. (Nasdaq: OTIC) will announce its first quarter 2022 financial results and corporate update on May 9, 2022, at 4:30 p.m. ET. Investors can participate in the live call by calling (877) 305-6769 or (678) 562-4239 for international access, using conference ID 5359095. A webcast of the event will be available on the company's investor relations website, archived for 30 days. Otonomy is focused on innovative therapeutics for neurotology, particularly addressing hearing loss and tinnitus through advanced drug delivery technology.

Positive

• Upcoming financial results announcement may provide insight into company performance.
• Focus on innovative therapeutics for neurotology addresses a significant market need.

Negative

• None.

SAN DIEGO, May 02, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the first quarter 2022 and provide a corporate update at 4:30 p.m. ET on May 9, 2022.

The live call may be accessed by dialing (877) 305-6769 for domestic callers and (678) 562-4239 for international callers with conference ID code number: 5359095. A live webcast of the call will be available online in the investor relations section of Otonomy’s website at www.otonomy.com and will be archived there for 30 days.

About Otonomy

Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs with a focus on hearing loss and tinnitus. For additional information, please visit www.otonomy.com.

Contacts:

Media Inquiries:
Spectrum Science
Lauren Benton
Senior Account Executive
212.899.9731
lbenton@spectrumscience.com

Investor Inquiries:
ICR Westwicke
Robert H. Uhl
Managing Director
858.356.5932
robert.uhl@westwicke.com

FAQ

When will Otonomy report its financial results for Q1 2022?

Otonomy will report its financial results on May 9, 2022, at 4:30 p.m. ET.

How can I access Otonomy's financial results call?

The call can be accessed by dialing (877) 305-6769 for domestic callers or (678) 562-4239 for international callers, using conference ID 5359095.

What is Otonomy's focus in the biopharmaceutical market?

Otonomy is focused on developing innovative therapeutics for neurotology, specifically targeting hearing loss and tinnitus.